DGX (Quest Diagnostics Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by DGX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | J. E. Davis | CEO and President | Sell | — | — |
| 2026-08-31 | MICHAEL E PREVOZNIK | SVP & General Counsel | MIXED | — | — |
| 2026-07-29 | MARK E DELANEY | SVP & Chief Commercial Officer | Sell | — | — |
| 2026-07-27 | SAM SAMAD | Executive Vice President & CFO | A | — | — |
| 2026-07-27 | MARK E DELANEY | SVP & Chief Commercial Officer | L | — | — |
| 2026-07-27 | ROBERT B CARTER | Director | L | — | — |
| 2026-07-27 | Patrick Plewman | SVP for Diagnostic Services | L | — | — |
| 2026-07-27 | Vicky B Gregg | Director | A | — | — |
| 2026-07-27 | Wright Lassiter III | Director | L | — | — |
| 2026-07-27 | TIMOTHY L MAIN | Director | L | — | — |
| 2026-07-27 | KARTHIK KUPPUSAMY | SVP, Clinical Solutions | L | — | — |
| 2026-07-02 | TIMOTHY C WENTWORTH | Director | A | — | — |
| 2026-06-08 | KARTHIK KUPPUSAMY | SVP, Clinical Solutions | MIXED | — | — |
| 2026-06-02 | J. E. Davis | CEO and President | Sell | — | — |
| 2026-05-21 | GARY M PFEIFFER | Director | A | — | — |
| 2026-05-21 | DENISE M MORRISON | Director | A | — | — |
| 2026-05-21 | Wright Lassiter III | Director | A | — | — |
| 2026-05-21 | TIMOTHY M RING | Director | A | — | — |
| 2026-05-21 | Tracey Doi | Director | A | — | — |
| 2026-05-21 | TIMOTHY C WENTWORTH | Director | A | — | — |
| 2026-05-21 | TIMOTHY L MAIN | Director | A | — | — |
| 2026-05-21 | Luis Diaz | Director | A | — | — |
| 2026-05-21 | Vicky B Gregg | Director | A | — | — |
| 2026-05-21 | ROBERT B CARTER | Director | A | — | — |
| 2026-04-24 | MARK E DELANEY | SVP & Chief Commercial Officer | L | — | — |
| 2026-04-24 | KARTHIK KUPPUSAMY | SVP, Clinical Solutions | L | — | — |
| 2026-04-24 | Wright Lassiter III | Director | L | — | — |
| 2026-04-24 | ROBERT B CARTER | Director | L | — | — |
| 2026-04-24 | Vicky B Gregg | Director | A | — | — |
| 2026-04-24 | Patrick Plewman | SVP for Diagnostic Services | L | — | — |
| 2026-04-24 | SAM SAMAD | Executive Vice President & CFO | A | — | — |
| 2026-04-02 | TIMOTHY C WENTWORTH | Director | A | — | — |
| 2026-03-11 | TIMOTHY C WENTWORTH | Director | A | — | — |
| 2026-03-06 | KARTHIK KUPPUSAMY | SVP, Clinical Solutions | MIXED | — | — |
| 2026-03-06 | Michael J Deppe | SVP, Corp. Controller & CAO | MIXED | — | — |
| 2026-03-06 | Patrick Plewman | SVP for Diagnostic Services | MIXED | — | — |
| 2026-03-06 | J. E. Davis | CEO and President | MIXED | — | — |
| 2026-03-06 | MICHAEL E PREVOZNIK | SVP & General Counsel | MIXED | — | — |
| 2026-03-06 | MARK E DELANEY | SVP & Chief Commercial Officer | MIXED | — | — |
| 2026-03-06 | Catherine T. Doherty | EVP, Regional Businesses | MIXED | — | — |
| 2026-03-06 | SAM SAMAD | Executive Vice President & CFO | MIXED | — | — |
| 2026-03-04 | Michael J Deppe | SVP, Corp. Controller & CAO | F | — | — |
| 2026-03-04 | MARK E DELANEY | SVP & Chief Commercial Officer | F | — | — |
| 2026-03-04 | KARTHIK KUPPUSAMY | SVP, Clinical Solutions | F | — | — |
| 2026-03-04 | Patrick Plewman | SVP for Diagnostic Services | MIXED | — | — |
| 2026-03-04 | J. E. Davis | CEO and President | MIXED | — | — |
| 2026-03-04 | MICHAEL E PREVOZNIK | SVP & General Counsel | MIXED | — | — |
| 2026-03-04 | SAM SAMAD | Executive Vice President & CFO | F | — | — |
| 2026-03-04 | Catherine T. Doherty | EVP, Regional Businesses | MIXED | — | — |
| 2026-02-20 | Vicky B Gregg | Director | L | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 15,377,551 | — |
| — | Chairman, CEO and President | 428,201 | — |
| — | Chairman, President & CEO | 248,936 | — |
| — | SVP & Chief Financial Officer | 163,806 | — |
| — | CEO and President | 122,423 | — |
| — | Executive Vice President & CFO | 109,456 | — |
| — | SVP & Group Exec. Diag. Sol. | 97,389 | — |
| — | SVP-Oncology & Neurology Srvcs | 90,279 | — |
| — | EVP, Regional Businesses | 71,624 | — |
| — | Director | 56,225 | — |
| — | SVP, Advanced Diagnostics | 48,391 | — |
| — | Vice President, Operations | 47,752 | — |
| — | SVP & General Counsel | 43,767 | — |
| — | SVP, Commercial | 38,481 | — |
| — | SVP, Corp. Controller & CAO | 36,652 | — |
| — | SVP, Diagnostic Testing Ops | 36,084 | — |
| — | Director | 33,951 | — |
| — | Director | 33,881 | — |
| — | Executive Vice President & CFO | 33,478 | — |
| — | Director | 31,140 | — |
| — | Director | 31,005 | — |
| — | SVP & Chief Commercial Officer | 29,045 | — |
| — | Director | 27,460 | — |
| — | Director | 20,504 | — |
| — | SVP, Operations | 19,890 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DGX quote page; the site-wide leaderboard is on the insider transactions hub.